Migrating leukocytes are the source of Peroxiredoxin V during inflammation in the airways
© Krutilina et al; licensee BioMed Central Ltd. 2006
Received: 29 March 2006
Accepted: 04 October 2006
Published: 04 October 2006
We characterized changes in expression of the antioxidant protein Peroxiredoxin V (PRXV) during airway inflammation.
Studies in anesthetized rats and mice; PRXV expression determined by Western blot analyses and immunohistochemistry; PRXV m-RNA expression determined by Taq-Man RT-PCR.
Bacterial lung inflammation did not change expression of PRXV in murine epithelia but produced massive influx of leukocytes highly expressing PRXV. Endotoxin and f-MLP induced leukocyte migration in rat trachea but did not change mRNA levels and PRXV protein expression in tracheal epithelial cells. In primary airway cell culture (cow), alveolar epithelial cells A549, or co-culture of A549 with murine macrophages RAW264.7, exposure to live bacteria increased expression of PRXV, which required serum. PRXV was secreted in vitro by epithelial and immune cells.
Inflammation increased expression of PRXV in airways by at least 2 mechanisms: cell population shift by massive influx of leukocytes expressing PRXV, and moderate post-transcriptional up-regulation of PRXV in epithelial cells.
To ensure adequate protection against oxidative stress during states of pulmonary disease, several antioxidant systems have evolved in the epithelial cells of mammalian airways [1–4]. Peroxiredoxins I-VI (PRX I-VI) are a group of potent antioxidant proteins that are the subject of much research [5–10]. PRXs neutralize reactive oxygen by transferring electrons from thioredoxins or cyclophilins. The six PRXs differ in their intracellular distribution and are thought to serve different functions and be regulated by different mechanisms. PRXV is one of the key enzymes of cellular antioxidant defense, as it is a potent protector against DNA damage and also has other functions [11–14].
Toxic insults to the respiratory tract down-regulate synthesis of the PRXV protein. We have recently demonstrated in vivo in rat tracheal epithelial cells that cigarette smoke extract (CSE) directly down-regulated expression of PRXV, which is one mechanism of cigarette smoke toxicity . Exposure of isolated tracheal segment to CSE significantly reduced mRNA levels for PRXV and the amount of PRXV protein in the epithelium. In cultures of the tracheal epithelial cell lines, primary airway cell culture, and the alveolar epithelial cells A549, CSE significantly decreased transepithelial electrical resistance, expression of PRXV protein, and significantly induced glutathione and protein oxidation. Similarly, when respiratory tract toxicity was induced in mice with naphthalene, the loss of the Clara cell population was associated with a significant decrease in PRXV expression . In contrast, previous reports had indicated that PRXV was over-expressed in the lung during inflammation induced by endotoxin . However, experiments in vitro in which pro-inflammatory cytokines were added to human alveolar or bronchial epithelial cells did not result in an up-regulated expression of PRXV . Neither the mechanism by which PRXV is up-regulated during inflammation in tissues of the lung nor the identity of the cells that are the source of PRXV production are known.
We therefore investigated the effects of gram-negative bacterial inflammation on expression of PRXV in lung, lung epithelial cells, and immune cells in vivo and in vitro. Our first aim was to determine whether inflammation in vivo influences expression of PRXV in the bronchial epithelium and alveoli. Our second aim was to use an in vivo model of inflammation to investigate whether changes of transcription or translation of PRXV in the tracheal epithelium, if they occurred, were a direct response to bacterial pathogen lipopolysaccharide (LPS) by these cells or whether the increased level of PRXV was induced by leukocyte migration. Our third aim was to determine in vitro whether exposure of the airway and alveolar epithelial cells to live bacteria, either alone or in co-culture with murine macrophages RAW264.7 changes the level of PRXV mRNA as well as protein expression and secretion.
We found that both in vivo and in vitro inflammation induced by bacteria resulted in an increased expression of PRXV in the airway epithelium by at least 2 different mechanisms: massive influx of activated leukocytes, which highly express PRXV, and moderate translational up-regulation of PRXV in the epithelial cells.
1. In vivo studies
Experiments in animals were performed according to protocols approved by the Institutional Animal Use Committee of the Children's Hospital Oakland Research Institute and Institute of Cytology, RAS.
Experiments in mice
Recipient mice (n = 12) were given a sub-lethal dose of whole-body irradiation (5.05 Gy) the day before transplantation. While under general anesthesia (Pentobarbital, 25 mg/kg IP), the mice were infused with 106 whole bone-marrow cells in 0.2 ml of PBS into the jugular vein.
Bacterial lung injury
In the experimental group, six chimeric mice received intratracheal instillation of PBS (n = 3, control) or 7 × 106 cfu of E. coli K12 JM109 in 50 μl of PBS; the chimeric model has been described previously . As a secondary control group for the bacterial inflammation study, 3 non-chimeric C57BL/6 mice received 7 × 106 cfu of E. coli, while 3 non-chimeric mice without known lung pathology were used as controls. These mice were euthanized and studied 1–2 weeks after the E. coli instillation.
Experiments in rats
Perfusion of rat trachea
An anesthetized Sprague-Dawley rat model of an in situ perfusion of isolated tracheal segment with an intact blood supply was used, as described previously . Experimental groups: Control group (n = 6): In the control group, tracheal segments were filled with PBS and sampled at 2 and 4 hours thereafter. Induced leukocyte migration (n = 4): In this group, 5 × 10-8 M f-MLP (final concentration) was added to tracheal lumen in PBS and samples were taken at 4 hours. Endotoxin model (n = 4): In this group, LPS E. coli O55:B5 at a concentration of 100 μg/ml was applied to the inner trachea for 4 hours.
At the end of the experiment in all groups, tracheal lumen was thoroughly washed, and samples of the epithelial layer from the tracheas were cut out, frozen in liquid nitrogen, and further used for RT-PCR or immunohistochemical analyses to determine expression of mRNA or PRXV protein.
2. In vitro cell culture experiments
Cell culture techniques used have been described previously .
A549 (ATCC) cells were grown in Hank's F12 K medium with 2 mM L-glutamine, 10% fetal bovine serum (FCS) (Life Technologies, Gaithersburg, MD), and streptomycin/penicillin. Co-culture experiments were performed in DMEM with or without 10% heat-inactivated FCS. P. aeruginosa PAO1 was added for 12–24 hours to the apical surface at a concentration of 5 × 107 cfu/ml. Following exposure, cells were washed 3 times with PBS and then either fixed with 4% paraformaldehyde for 24 hours for IHC or collected for Western blot analyses in cell lysis buffer on ice. Experiments were performed in triplicate in 3 different cultures.
Bronchial epithelial cells Calu-3 (ATCC) (gift of Dr. T. Machen, University of California, Berkeley) were grown on the internal surface of polycarbonate membranes (0.3 μm pore size, 6.5 mm diameter) in Transwells (Costar, Cambridge, MA) with an air-liquid interface. These cells were similarly exposed to PAO1 for 12 hours at a concentration of 5 × 107 cfu/ml. TER, a measure of tight junctional permeability, was measured with a voltmeter (EVOMX-G, World Precision Instruments, Sarasota, FL). CTE cells were grown and studied similarly. Primary cultures of cow tracheal epithelial (CTE) cells was performed as follows: Surface of the cow tracheas was scored into thin strips and those were separated from the underlying cartilage rings and placed in cold phosphate buffered saline (PBS) + PSFG (Penicillin, Streptomycin, Fungizone, Gentamycin). Strips were placed in 40 ml of Hank's BSS, Ca2+/Mg2+ free + PSFG with 1 mg/ml protease (Sigma Co), and digested overnight at 4°C. Strips were then resuspended in DME H21/F-12 mix + 5% FCS + PSFG, shaken vigorously to pull the cells off. The cell suspension was centrifuged for 10 minutes at 1000 rpm. The cells were plated 106 cells/cm2 on 3 μ pore polycarbonate membranes and grown in DME-H21/F-12 mix with PSFG and a mixture of growth factors consisting of transferrin, insulin, triiodothyronine, hydrocortisone, endothelial cell growth supplement, and epidermal growth factor. As CTE cells were more resistant to PAO1 than were the Calu-3, exposure to 5 × 107 cfu/ml of bacteria was extended to 12 hours.
RAW 264.7 (ATCC) were grown in RPMI-1640 with 15% FCS, THP-1 (ATCC) were grown in RPMI-1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol, 10% FCS.
3. Western Blot analyses and immunohistochemistry
These were performed as described previously . Antibodies used: Anti-Green Fluorescent Protein rabbit IgG, 1:50, (Molecular Probes, Eugene, OR), rat anti-mouse CD45 antibody 1:10 (Calbiochem San Diego, CA), secondary anti-rat, anti-rabbit antibodies (Molecular Probes,, Eugene, OR). Our own anti-PRXV rabbit antibody  at 1:200 dilution was used for PRXV staining.
4. Analyses of PRXV mRNA expression
Taq-Man analyses were performed at the University of California, Davis, Lucy Whittier Molecular and Diagnostic Core Facility, at the Department of Medicine and Epidemiology by using standard techniques. For rat PRXV gene, pre-developed TaqMan PCR assay (Rn00586040-m1) was purchased from Applied BioSystems (Foster City, CA). In order to determine the most stably transcribed housekeeping gene, a housekeeping gene validation experiment was conducted on a representative number of samples. The housekeeping gene with the least standard deviation in all treatment groups (HPRT1 or TFR2) was used to normalize the target gene CT values. All gene transcriptions were expressed and are presented here as an n-fold difference relative to the calibrator.
5. Statistical analyses
At least six different sections from each lung were used for analyses. Cell counting was performed in 20 different randomly selected visual fields. Numbers of GFP+ cells were determined as a percentage of the total number of cells (counted by numbers of PI-stained nuclei). In antibody-specific staining, numbers of ligand-positive cells were expressed as a percentage of the total numbers of GFP+ cells in 20 different visual fields. Fluorescence intensity in cells was determined by built-in Zeiss LSM software options. Western blot analyses was performed in samples from 3 different cultures; results were quantified by photometry. Data are presented as the MEAN ± SE, statistical significance by ANOVA or Student's t-test was established at p < 0.05.
1. Migrating leukocytes are the source of PRXV in the lung
Half of the mice subjected to LD50 intratracheal instillation of live E. coli died from pneumonia within 1 week. In the surviving mice, the peak of lung inflammation (7 days after E. coli instillation) was predominantly associated with the influx of GFP+ leukocytes, which represented 16 ± 3 % of total lung cells. 95% of GFP+ cells in the lung were CD45+ cells.
2. PRXV protein expression is up-regulated in rat tracheal epithelium cells by f-MLP
We then used a perfused tracheal segment in vivo rat model to determine whether short-term (4 hours) exposure to f-MLP (induced leukocyte migration) or bacterial (E. coli) LPS would enhance transcription and translation of PRXV in the tracheal epithelium. Following exposure to f-MLP or LPS, the tracheal segment was carefully washed off the cells in the lumen. In our previous studies, 4 hours of exposure of tracheal segment to f-MLP resulted in enhanced leukocyte migration and increased permeability [19, 20]. We therefore used this time period to assess expression of PRXV in the model of inflammation. In the f-MLP model of inflammation, a 4-hour exposure of the isolated tracheal segment to f-MLP provided a small (32%) yet significant (p < 0.05) increase in the PRXV expression in the cells of tracheal epithelium (from 182 ± 16 relative units in the control to 241 ± 3 relative units in the experimental group), but not in mRNA levels (2.36 ± 0.23 in the control versus 1.51 ± 0.22 in the experimental group). In the LPS model, we also did not observe statistically significant difference in PRXV mRNA levels in the tracheal epithelium (4.71 ± 0.9 in the control versus 2.3 ± 0.7 in the LPS experiment model). There were no significant differences in PRXV protein expression in the epithelium (data not shown).
3. Live P. aeruginosa bacteria up-regulates expression, but not transcription, of PRXV in cultured airway epithelium in the presence of serum
Unlike Calu-3, the primary cultures of cow tracheal epithelium showed a pattern of increased PRXV expression after exposure to bacteria which was similar to the pattern shown by the A549 cells (Figure 5C).
We investigated both in vivo and in vitro models of the lung bacterial inflammation. In mice, rats, and cultures of human airway epithelium cells, PRXV was abundantly expressed under non-inflammatory control conditions. In rats, neither the presence of endotoxins nor f-MLP-induced migration of leukocytes in the tracheal epithelium changed mRNA levels of PRXV; f-MLP slightly increased expression of PRXV protein in the tracheal epithelium. In mice, bacterial inflammation of the lung resulted in a massive influx of leukocytes, which were the source of the increased PRXV in the lung tissues. In primary airway cell culture (cow) and alveolar epithelial cells A549, or co-culture of the epithelial cells with murine macrophages RAW264.7, exposure to live bacteria mildly, yet significantly, increased expression of PRXV protein. Transcription of PRXV protein was not increased by exposure to bacteria in the A549 or Calu-3 cells. PRXV was secreted in vitro by both the epithelial and immune cells.
PRXV is a protein abundantly expressed under the baseline conditions in the airway epithelium, and these observations suggest that the major pathophysiological mechanism of its overall up-regulation in the lung during gram-negative bacterial inflammation is a shift in tissue cell populations due to migrating leukocytes. In the in vitro cultured airway epithelia, expression of PRXV protein was only moderately up-regulated in bacterial inflammation, while no transcriptional up-regulation was observed.
Our experimental finding that serum is required for the effect of PAO1 on up-regulation of PRXV may have several explanations. The most obvious is that recognition of bacteria by epithelial cells requires serum factors. Epithelial cells, unlike immune cells, do not possess receptors of innate immunity (Toll receptors and auxiliary proteins) in sufficient quantity. It is known, that epithelial and endothelial cells without the presence of immune cells are activated with bacterial products like lipopolysaccharide only in the presence serum. Generation of a response to bacterial products in non-immune cells occur only at a very high levels of bacterial product concentrations. We did not observe up-regulation of PRXV in co-culture of the epithelial and immune cells. Inflammatory reactions are complex even in this simplified in vitro model, with multiple loops of feedback regulation, both positive and negative. Likely, PAO1 caused activation of RAWs and possibly apoptosis of these cells. Activated RAWs release an array of pro-inflammatory cytokines, which might initiate apoptosis in epithelial cells and therefore decrease PRXV expression. The fate of RAWs co-cultured with the epithelial cells is difficult to estimate, but very likely RAWs did not have much survival advantage in the medium designed for epithelial cells.
Prior studies of PRX expression showed that PRXI, II, III, V and VI are highly over-expressed in the human lung cancer cells . Allergic inflammation in response to ovalbumin induced overexpression of PRXI , which is also well known to be induced by hyperoxia . Stimulation of the A549 cells and BEAS 2 B cells with hydrogen peroxide, menadione, tumor necrosis factor α, or transforming growth factor β did not result in significant changes of PRXV expression . These in vitro results are in agreement with our data.
In studies of secreted PRXV, we observed only a 60 kDa band by Western blot analyses. Peroxiredoxins may form polymers in an oxidized state. It is unlikely that the band of interest was non-specific staining, simply because it was observed only after stimulation, but not in control non-stimulated cells and not in serum. Further investigations are needed to define the mechanisms of PRXV polymerization in extra-cellular fluids.
Some insights into possible mechanisms of PRXV gene regulation can be obtained by analysis of the PRXV gene structure. The PRXV gene is located on human chromosome 11q13, which is a region of genetic linkage for atopic hypersensitivity such as bronchial asthma. A 5' promoter region (4 kb upstream of the first exon) contains 3 potential binding sites (hypoxia-response element HRE, motifs ACGTG for hypoxia-inducible transcription factor HIF-1 and one potential antioxidant/electrophile response element (ARE/EpRE, motif TGACNNNGC). Additional ARE/EpRE is also present within the first intron, along with potential binding sites for transcription factor NF-kappa-B (motif GGRNAKTCCC) and Alu-associated retinoic acid-response element (RARE, motif AGGTSMNNAGWTCR). Therefore, in theory, transcription of this gene can be modulated in response to hypoxia, inflammation, and oxidative stress by intrinsic regulatory elements. It should be noted, however, that the functional activity of these potential transcription elements in the human PRXV promoter region has not been confirmed experimentally.
According to our data from the in vivo studies, PRXV protein is already abundantly up-regulated, and it is not up-regulated further by inflammation. One explanation is that the mechanisms regulating PRXV transcription cannot further increase expression in these cells, which are in constant direct contact with pathogens, antigens, and oxidants from the environment that are present in the bronchial tree in vivo.
Cells of the alveolar lining, however, are protected from these stimuli. It is unclear why we did not observe up-regulation of PRXV in the alveolar epithelium in vivo during bacterial inflammation of the airways, though we observed mild up-regulation in the A549 cells in vitro. Very likely, the model of lung bacterial inflammation that we used (instillation of bacteria into the airways) affected primarily the upper and conducting airways without causing massive inflammation in the alveolar spaces.
Adequate antioxidant protection in the lung is required for normal function, especially under conditions of oxidant stress caused by environmental factors . Classic antioxidant enzymes of the lung cells that reduce hydrogen peroxide are catalase and glutathione peroxidase, while airway surface liquids and interstitial fluids are rich in superoxide dismutase and glutathione. Other hydrogen peroxide-reducing enzymes include thioredoxin-thioreductase, peroxiredoxins, and glutaredoxins . Under physiologic conditions, superoxide dismutases and glutathione peroxidase are much more efficient than peroxiredixins in regulating the cell redox state. Under conditions of high oxidative stress, however, enzymes like thioredoxin may become physiologically important . Hoshino and co-workers  showed that overexpression of thioredoxin or administration of its recombinant form protected mice against lung injury induced by pro-inflammatory cytokines and bleomycin. Adenovirus-mediated transfer of 1-cys peroxiredoxin gene was shown to protect mice from oxidative injury induced by exposure to oxygen . PRXV has multiple functions: in addition to its antioxidant activity, PRXV is also a transcriptional co-repressor [13, 14] and an inhibitor of p53-dependent apoptosis . The anti-apoptotic activity of PRXV was demonstrated in tendon cells .
Our results showed that acute inflammation in the lung results in up-regulation of PRXV expression by different mechanisms. In the bronchial epithelium, we observed only a moderate rise in expression of this protein on a post-transcriptional level. Activated leukocytes that move to the lungs when inflammation occurs are a rich source of PRXV. However, this is likely to be a mechanism of leukocyte self-defense against self-induced oxidation rather than the mechanism of tissue protection. Defining the mechanism of PRXV regulation of expression in leukocytes during activation by mitogens was not the aim of present investigation and requires further study. Nonetheless, as PRXV is normally abundantly expressed in airways and as mechanisms of further PRXV up-regulation in the bronchial epithelium are limited, there is a basis for proposing therapeutic administration of this protein in recombinant form. Administration of PRXV in aerosol form may have significant therapeutic potential, especially in conditions where PRXV expression is down-regulated . Inflammatory conditions are not the likely candidates for such an intervention, however, as there is no deficiency of PRXV in the airway epithelium during inflammation.
In vivo and in vitro bacterial inflammation mildly up-regulates expression of PRXV protein in the airway epithelial cells. An increased influx of activated leukocytes to inflamed tissues serves as a source of enhanced expression of PRXV in the lung.
bovine serum albumin
cigarette smoke extract
cow tracheal epithelium
fetal calf serum
- PBS :
- TER :
transepithelial electrical resistance.
Research described in this manuscript was supported by Philip Morris USA Inc. and by Philip Morris International. We would like to express our appreciation of technical assistance of Hyon Choi with cell cultures.
- Crapo JD: Redox active agents in inflammatory lung injury. Am J Resp Crit Care Med. 2003, 168: 1027-1028. 10.1164/rccm.2309001.PubMedView ArticleGoogle Scholar
- Kinnula VL: Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax. 2005, 60: 693-700. 10.1136/thx.2004.037473.PubMedPubMed CentralView ArticleGoogle Scholar
- Kinnula VL, Crapo JD: Superoxide dismutases in the lung and human lung diseases. Am J Resp Crit Care Med. 2003, 167: 1600-1619. 10.1164/rccm.200212-1479SO.PubMedView ArticleGoogle Scholar
- Rahman I, MacNee W: Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax. 1996, 51: 348-350.PubMedPubMed CentralView ArticleGoogle Scholar
- Kim HS, Kang SW, Rhee SG, Clerch LB: Rat lung peroxiredoxins I and II are differentially regulated during development and by hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2001, 280: L1212-L1217.PubMedGoogle Scholar
- Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R, Lakari E, Paakko P, Kang SW, Rhee SG, Soini Y: Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. Thorax. 2002, 57: 157-164. 10.1136/thorax.57.2.157.PubMedPubMed CentralView ArticleGoogle Scholar
- Manevich Y, Feinstein SI, Fisher AB: Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with GST. PNAS. 2004, 101: 3780-3785. 10.1073/pnas.0400181101.PubMedPubMed CentralView ArticleGoogle Scholar
- Wang Y, Manevich Y, Feinstein SI, Fisher AB: Adenovirus-mediated transfer of the 1-cys peroxiredoxin gene to mouse lung protects against hyperoxic injury. Am J Physiol Lung Cell Mol Physiol. 2004, 286: L1188-L1193. 10.1152/ajplung.00288.2003.PubMedView ArticleGoogle Scholar
- Yuan J, Murrell GAC, Trickett A, Landtmeters M, Knoops B, Wang M-X: Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. Biochim et Biophys Acta – Mol Cell Res. 2004, 1693: 37-45. 10.1016/j.bbamcr.2004.04.006.View ArticleGoogle Scholar
- Zhou Y, Kok KH, Chun AC, Wong CM, Wu HW, Lin MC, Fung PC, Kung H, Jin DY: Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis. Biochem Biophys Res Comm. 2000, 24: 921-927. 10.1006/bbrc.2000.2231.View ArticleGoogle Scholar
- Kropotov AV, Grudinkin PS, Pleskach NM, Gavrilov BA, Tomilin NV, Zhivotovsky BD: Down-regulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. FEBS Letters. 2000, 572: 75-79. 10.1016/j.febslet.2004.07.011.View ArticleGoogle Scholar
- Kropotov AV, Sedova V, Ivanov V, Sazeeva N, Tomilin A, Krutilina RI, Oei SL, Griesenbeck J, Buchlow G, Tomilin NV: A novel human DNA-binding protein with sequence similarity to a subfamily of redox proteins, which is able to repress RNA-polymerase-III-driven transcription of the Alu-family retroposons in vitro. Eur J Biochem. 1999, 260: 336-346. 10.1046/j.1432-1327.1999.00162.x.PubMedView ArticleGoogle Scholar
- Kropotov AV, Tomilin NV: A human B-box-binding protein down-regulated in adenovirus 5-transformed human cells. FEBS Letters. 1996, 386: 43-46. 10.1016/0014-5793(96)00353-5.PubMedView ArticleGoogle Scholar
- Kropotov AV, Tomilin NV: Evidence for a regulatory protein complex on RNA polymerase III promoter of human retroposons of Alu family. Genetica. 1997, 98: 223-233. 10.1007/BF00057587.View ArticleGoogle Scholar
- Serikov VB, Leutenegger C, Krutilina RI, Kropotov AV, Pleskach NM, Jung Suh, Tomilin NV: Cigarette Smoke Extract Inhibits Expression of Peroxiredoxin V and Increases Airway Epithelial Permeability. Inhalation Toxicology. 2006, 18: 79-92.PubMedView ArticleGoogle Scholar
- Serikov VB, Popov BV, Kropotov AV, Tomilin NV: Bone Marrow-Derived Cells Restore Expression of Peroxiredoxin V in the Airways Following Acute Naphthalene Injury in Mice. Cytotherapy. 2005, 7: 483-493. 10.1080/14653240500361012.PubMedView ArticleGoogle Scholar
- Knoops B, Clippe A, Bogard C, Arsalane K, Wattiez R, Hermans C, Duconseille E, Falmagne P, Bernard A: Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. J Biol Chem. 1999, 274: 30451-30458. 10.1074/jbc.274.43.30451.PubMedView ArticleGoogle Scholar
- Lehtonen ST, Markkanen PMH, Peltoniemi M, Sang Won Kang, Kinnula VL: Variable over-oxidation of peroxiredoxins in human lung cells in severe oxidative stress. Am J Physiol: Lung Cellular and Molecular Physiology. 2005, 288: L997-L1001. 10.1152/ajplung.00432.2004.Google Scholar
- Serikov VB, Jang JY, Widdicombe JH: An estimate of hydrostatic pressure which drives fluid into airway lumen. J Appl Physiol. 2002, 92: 1702-1708.PubMedView ArticleGoogle Scholar
- Serikov VB, Choi H, Chmiel KJ, Wu R, Widdicombe JH: Role of ERK in the increase in airway epithelial permeability during leukocyte transmigration. Am J Resp Cell Mol Biol. 2004, 30: 261-270. 10.1165/rcmb.2003-0053OC.View ArticleGoogle Scholar
- Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, Kinnula VL: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004, 111: 514-21. 10.1002/ijc.20294.PubMedView ArticleGoogle Scholar
- Fajardo I, Svensson L, Bucht A, Pejler G: Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. Am J Respir Crit Care Med. 2004, 170: 477-484. 10.1164/rccm.200402-178OC.PubMedView ArticleGoogle Scholar
- Das KC, Pahl PM, Guo XL, White CW: Induction of peroxiredoxin gene expression by oxygen in lungs of newborn primates. Am J Respir Cell Mol Biol. 2001, 25: 226-232.PubMedView ArticleGoogle Scholar
- Tomoaki Hoshino, Hajime Nakamura, Masaki Okamoto, Seiya Kato, Shinichi Araya, Keiko Nomiyama, Kotaro Oizumi, Young HA, Hisamichi Aizawa, Junji Yodoi: Redox-reactive protein Thioredoxin prevents proinflammatory cytokine- or Bleomycin-induced lung injury. Am J Resp and Crit Care Medicine. 2003, 168: 1075-1083. 10.1164/rccm.200209-982OC.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.